Thermo Fisher Scientific Announces New Cryo-TEM with Expansive Automation Features to Help Accelerate Drug Discovery Research
Thermo Scientific Glacios 2 Cryo-TEM designed to be the next evolution in cryo-electron microscopy with enhanced throughput and high-resolution imaging capabilities
HILLSBORO, Ore.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific Glacios 2 Cryo-Transmission Electron Microscope (Cryo-TEM), a powerful microscope with new automation and high-resolution imaging capabilities designed to help cryo-electron microscopy (cryo-EM) researchers of varying experience levels accelerate structure-based drug discovery. This advanced, fast and cost-efficient method for drug design may enable customers to accelerate the pace of research for debilitating disorders like Alzheimer’s, Parkinson’s, and Huntington’s diseases, as well as research for cancer and gene mutations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005063/en/
Thermo Scientific Glacios 2 Cryo-TEM (Photo: Business Wire)
The Glacios 2 Cryo-TEM includes automation features designed to extend accessibility to a range of cryo-EM techniques, including single particle analysis, cryo-electron tomography (cryo-ET) and microcrystal electron diffraction (MicroED). Additional highlights include fringe-free imaging for the acquisition of more usable images per foil hole, increased throughput compared to other commercially available optical alignment solutions and a new enclosure and hardware improvements built to offer enhanced performance compared to prior models.
This next generation solution can generate <2 angstrom 3D reconstructions and produce images faster than its predecessor. These capabilities can help users of all experience levels increase productivity at a time when rapid innovation and emerging cryo-EM applications are placing increasing demands on expert microscopists.
“Using the Glacios 2 Cryo-TEM, we developed a workflow that enables us to determine structures of small, asymmetric complexes at high resolution and with high throughput,” said Basil Greber, principal investigator for The Greber Laboratory at the Institute of Cancer Research and beta user of the new Glacios 2 Cryo-TEM. “Uncovering such structures provides us with detailed insight into inhibitor binding and suggests a mechanism for target selectivity in cancer therapeutics that we are currently testing.”
The new system also includes Thermo Scientific Smart EPU Software, which contains components needed for automated data acquisition, including microscope alignment and readiness assistance, plus an open API to allow for the development of solutions tailored to a user’s needs.
“As the demand for cryo-EM continues to surge, automated, high-throughput instruments are critical to advancing life science research around the world—especially in the fast-paced pharmaceutical and biotech industries,” said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher Scientific. “The Glacios 2 Cryo-TEM meets these needs by delivering high-quality structures quickly, taking some of the pressures away from microscope operation and giving time back to the scientists to focus on their groundbreaking research.”
For pharma and biotech companies, the Glacios 2 Cryo-TEM offers high-throughput screening and imaging to enable the routine structure generation of druggable targets, including key targets of <120 kDA in size. For labs with growing demand for cryo-EM, the Glacios 2 solution helps increase accessibility to near atomic resolution structures, while improving ease-of-use and reproducibility across a variety of workflows.
Learn more about the Thermo Scientific Glacios 2 Cryo-TEM: https://ter.li/o0aomq
Register for a webinar on October 18 about new Glacios 2 Cryo-TEM-enabled research with Basil Greber: https://ter.li/1nbhgi
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Thermo Fisher Scientific
Source: Thermo Fisher